Quest Diagnostics Receives New York State Approval for Haystack MRD, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

Quest Diagnostics received New York State approval for its Haystack MRD ctDNA minimal residual disease test, broadening patient access to the assay.